Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective post marketing surveillance study to be performed in
Sweden. Only data of patients idiopathic PD should be documented, in whom the treating
physician plans to initiate a pharmacotherapy with PPX ER independent of this observational
study. The questionnaires (Morisky Medication Adherence Measure, patient preference scale,
CGI-I, PGI-I) will be used to document routine care in a standardized way and thus ensure
high validity of the observational data. As the degree medication adherence of patients is
routinely evaluated by their physicians, as is patient preference and possible symptom
improvement after initiation of a new therapy, the patient questionnaires will be used to
standardise medical routine care and to ensure validity of observational data.